These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32264801)

  • 1. Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults.
    Agbese E; Leslie DL; Manhapra A; Rosenheck R
    Psychiatr Serv; 2020 Aug; 71(8):779-788. PubMed ID: 32264801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
    Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
    JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
    McCann NC; LaRochelle MR; Morgan JR
    J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Linas BP; Walley AY; LaRochelle MR
    Med Care; 2022 Mar; 60(3):256-263. PubMed ID: 35026792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
    Dunphy C; Peterson C; Zhang K; Jones CM
    Drug Alcohol Depend; 2021 Aug; 225():108784. PubMed ID: 34049104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.
    Roberts AW; Saloner B; Dusetzina SB
    Psychiatr Serv; 2018 Jul; 69(7):832-835. PubMed ID: 29734918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
    J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
    Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
    Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.
    Al Faysal J; Noor-E-Alam M; Young GJ; Lo-Ciganic WH; Goodin AJ; Huang JL; Wilson DL; Park TW; Hasan MM
    Comput Biol Med; 2024 Jul; 177():108493. PubMed ID: 38833799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
    Williams AR; Samples H; Crystal S; Olfson M
    Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population.
    Hasan MM; Noor-E-Alam M; Shi J; Young LD; Young GJ
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):481-491. PubMed ID: 35670828
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.
    Anderson KE; Saloner B; Eckstein J; Chaisson CE; Scholle SH; Niles L; Dy S; Alexander GC
    Med Care; 2021 May; 59(5):393-401. PubMed ID: 33734194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
    Wilder C; Lewis D; Winhusen T
    Drug Alcohol Depend; 2015 Apr; 149():225-31. PubMed ID: 25735465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.